Latest Trastuzumab Stories
Adding trastuzumab (trade name Herceptin) to the treatment offered to women who have HER2-positive breast cancer, significantly increases the chance of life being prolonged, and reduces the chance of tumours reappearing once therapy stops.
An international team of scientists, including four at Simon Fraser University, has made a discovery that will change the way the most deadly form of breast cancer is treated.
A new study has identified a key mechanism that causes breast cancer to spread.
In a review article posted online March 16 in Cell, the researchers say that refinements and modifications of monoclonal antibody drugs -- several of which have already revolutionized the care of breast and colon cancer --are now being tested in most tumor types.
A study headed up by the Vall d'Hebron Institute of Oncology (VHIO) heralds a new horizon in the fight against cancer, opening up a parallel dimension to existing treatment options.
Breast cancers expressing the protein HER2 have a particularly poor prognosis.